Bioxytran, Inc. Share Price

BIXT

US09075D1028

Biotechnology & Medical Research

Delayed OTC Markets Other stock markets 20:32:30 14/01/2026 GMT			5-day change	1st Jan Change
0.0600 ^USD	-11.37%		-12.02%	-20.84%

12-15	Bioxytran, Inc. Announces Resignation of Anders Utter from Board of Directors and Chair of Audit Committee	CI
11-14	Bioxytran, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI

Bioxytran, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development, manufacture, and commercialization of therapeutic drugs designed to address hypoxia in humans. The Company's lead drug candidate, code named BXT-25, is an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer with an intended application, which includes the treatment of hypoxic conditions in the brain resulting from stroke. The Company, through its subsidiary, Pharmalectin Inc., is focused on the development, manufacturing, and commercialization of therapeutic drugs designed to address viral diseases in humans. Pharmalectin Inc. has developed a method designed to reduce the viral load and modulate the immune system using a galectin inhibitor. Its lead drug candidate, named ProLectin-Rx, is a complex polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
14/01/26	0.0600 $	-11.37%	65,295
13/01/26	0.0677 $	-3.29%	253,092
12/01/26	0.0700 $	-5.41%	23,206
09/01/26	0.0740 $	-1.20%	76,722
08/01/26	0.0749 $	+9.79%	2,000

Delayed Quote OTC Markets, January 14, 2026 at 08:32 pm

More quotes

Income Statement and Estimates

More financial data

Annual profits - Rate of surprise

Rankings

Rankings

Currency / Forex

Commodities

Cryptocurrencies

Interest Rates

Interest Rates Area

All transcripts on over 9000 companies, on the day they post their earnings!

Unlock them now!

Capitalization	7.32M 6.28M 5.85M 5.44M 10.16M 661M 10.95M 67.25M 26.46M 316M 27.46M 26.89M 1.16B	P/E ratio 2025 *	-	P/E ratio 2026 *	-
Enterprise value	7.32M 6.28M 5.85M 5.44M 10.16M 661M 10.95M 67.25M 26.46M 316M 27.46M 26.89M 1.16B	EV / Sales 2025 *	-	EV / Sales 2026 *	-
Free-Float	53.75%	Yield 2025 *	-	Yield 2026 *	-

12-15	Bioxytran, Inc. Announces Resignation of Anders Utter from Board of Directors and Chair of Audit Committee	CI
11-14	Bioxytran, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-13	Bioxytran, Inc. announced that it has received $0.43 million in funding	CI
11-04	Bioxytran, Inc. announced that it expects to receive $0.43 million in funding	CI
29/10/25	Bioxytran Completes Randomized Clinical Trial for Its Broad-Spectrum Antiviral Drug	CI
29/10/25	Bioxytran completes randomized clinical trial for its broad-spectrum antiviral drug	RE
15/08/25	Bioxytran Unveils Revolutionary Precision Diagnostics on Tissue Oxygenation	CI
11/08/25	Bioxytran, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
07/08/25	Bioxytran's Breakthrough Broad-Spectrum Antiviral Technology Poised to Revolutionize Respiratory Infection Treatment	CI
21/05/25	Bioxytran's Antiviral Breakthrough Featured in University of Georgia's $100 Million Hpai Poultry Innovation Grand Challenge Submission	CI
15/05/25	Bioxytran, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
12/05/25	Bioxytran, Inc. Completes Dose Optimization of Antiviral, ProLectin-M	CI
03/04/25	Bioxytran, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI

11-13	Bioxytran Announces Initiation of Coverage of its Stock by Independent Research	AQ
29/10/25	Bioxytran Completes Randomized Clinical Trial For its Broad-Spectrum Antiviral Drug	AQ
15/08/25	Bioxytran Unveils Revolutionary Precision Diagnostics on Tissue Oxygenation	AQ
07/08/25	Bioxytran’s Breakthrough Broad-Spectrum Antiviral Technology Poised to Revolutionize Respiratory Infection Treatment	AQ
18/06/25	Bioxytran Secures a Source of GMP Quality Camel Hemoglobin	AQ

1 day	-11.37%
1 week	-12.02%
Current month	-20.84%
1 month	-8.26%
3 months	-14.16%
6 months	-41.52%
Current year	-20.84%

1 week	0.06	0.07
1 month	0.06	0.09
Current year	0.06	0.08
1 year	0.04	0.23
3 years	0.04	1.05
5 years	0	1.25
10 years	0	1.95

Bioxytran, Inc. Share Price

Equities

BIXT

US09075D1028

Biotechnology & Medical Research

Valuation: Bioxytran, Inc.

Chart: Bioxytran, Inc.

Latest news: Bioxytran, Inc.

Press Releases: Bioxytran, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Bioxytran, Inc.

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

Manager	Title	Age	Since
David Platt CEO	Chief Executive Officer	73	28/02/2018
Ola Soderquist DFI	Director of Finance/CFO	65	-
Leslie Ajayi CTO	Chief Tech/Sci/R&D Officer	-	-

Director	Title	Age	Since
Dale Conaway BRD	Director/Board Member	71	01/11/2018
Alan Hoberman BRD	Director/Board Member	73	01/11/2018
David Platt CHM	Chairman	73	28/02/2018

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
BIOXYTRAN, INC.	-11.37%	-12.02%	-35.14%	-86.37%	7.32M
ARGENX SE	-0.89%	+0.70%	+6.80%	+86.25%	49.64B
WUXI APPTEC CO., LTD.	-1.15%	+7.43%	+94.47%	+13.63%	44.64B
INSMED INCORPORATED	-1.04%	-7.94%	+137.25%	+747.38%	34.92B
BIONTECH SE	+1.79%	+8.76%	-3.19%	-23.99%	26.9B
GENMAB A/S	+4.89%	+6.38%	+44.02%	-18.56%	20.59B
WUXI BIOLOGICS (CAYMAN) INC.	+0.55%	+17.30%	+136.69%	-44.90%	21.08B
AKESO, INC.	+2.32%	+2.49%	+122.74%	+153.39%	14.24B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-3.00%	+5.76%	+177.12%	-	14.37B
SUMMIT THERAPEUTICS INC.	+4.34%	-7.84%	+5.23%	+281.70%	12.96B
Average	-0.37%	+2.59%	+68.60%	+123.17%	23.93B
Weighted average by Cap.	+0.28%	+3.03%	+72.74%	+154.90%

	2025 *	2026 *
Net sales	-	-
Net income	-	-
Net Debt	-	-